A Content Analysis of Cannabis Company Adherence to Marketing Requirements in Four States

In November 2021, Washington State passed Initiative Measure No. 502 (I-502) and Colorado passed Amendment 64, both of which legalized recreational, non-medical cannabis use for persons ages 21 and over. As of 2021, a total of 17 states have passed legislation allowing adult non-medical use of cannabis (National Conference of State Legislatures, 2021). Laws such as I-502 have led to concern about increased youth exposure and access to cannabis, which may be an unintended consequence of expanding adult access. Adolescents are a crucial at-risk population for cannabis use: rates of use among adolescents are approximately 15% for past-30-day use and 30% for lifetime use (Johnston et al., 2018). Consequences of adolescent cannabis use include academic difficulties such as dropping out of school, psychiatric impairment including memory loss, and progression to other drugs (Buckner et al., 2010; Green et al., 2010, 2017; Scott et al., 2018).

To read the full study published in the Journal of Studies on Alcohol and Drugs, click here:
https://www.jsad.com/doi/pdf/10.15288/jsad.2022.83.27

For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.

Visit the IASIC Library here (https://iasic1.org/library/). The IASIC Library is intended as a user-friendly reference of the published medical literature.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Related Posts

IASIC Speaker Series Presents  Cannabis and Mental Health

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Placebo Effect a Major Driver of Pain Reduction in Cannabis Trials

A strong placebo response may be largely responsible for the significant pain reduction observed in clinical trials of cannabis-based therapies, results of a new meta-analysis suggest. Investigators found that while the effect size of cannabinoids on pain intensity was significant, the placebo effect was about the same. “The data from the present meta-analysis, including 1459

Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration, 2005–2019

Since 2005, diagnoses of cannabis use disorder have increased substantially among VHA patients, as they have in the general population and other patient populations. Possible explanations warranting investigation include decreasing perception of risk, changing laws, increasing cannabis potency, stressors related to growing socioeconomic inequality, and use of cannabis to self-treat pain. Clinicians and the public

Cannabis legalization and cannabis-involved pregnancy hospitalizations in Colorado

The primary objective of this study was to evaluate the association between presence of recreational cannabis dispensaries and prevalence of cannabis-involved pregnancy hospitalizations in Colorado. This was a retrospective cohort study of pregnancy-related hospitalizations co-coded with cannabis diagnosis codes in the Colorado Hospital Association from January 1, 2011, through December 31, 2018 (recreational cannabis began

Scroll to Top